Member Info for allah4uk

With Brexit and a potential crash-out without financial agreements, you need to be wary when trading on continental stock exchanges.

For instance, due to a fall-out between Bruxelles and Bern, it is no longer possible to buy Swiss stocks using European brokers.

The same story could happen between Britain and the Union, involving the same restrictions.

Then there's the taxation. If you make the capital gains on a foreign market, they'll be taxed there.
You should make sure that you can claim these taxes back, or some of your gains will be wasted.

I hear you OP.

I was happy when we almost broke the 3€ barrier yesterday, and based on that, expected to reach the 5€ barrier by the end of May - at best.

Been gobsmacked by what I saw today.

Sod off deramper.

Looking at the share price today, I was actually thinking that the RNS *had been dropped*.
I find it amazing that the share's getting up without any new numbers. (Peston Effect ?
Hopefully we'll stay above 3 when the market closes.

Personally I'm betting on 3€ by the end of April, and 4€ by the end of May.

The question of the peak isn't an illegitimate one. But it remains to be seen what the governments will do in order to ensure the epidemic is on its way to being controlled, and there's no new peak eventually. I think testing is logically part of such an effort.

Pilgrim1 : "Partnering" can mean anything from lending help to being taken over. This term is meaningless without further precisions.

Primerdesign would have provided kits needed to perform benchmarks against their novel test.
Which would thus be a competitor, unless an agreement of sorts has been sealed.

Regardless on whether Boris Johnson makes it or not, I think his admission into the ICU could serve as a wake up call to those who were still taking the need for testing lightly.

The British government did get more serious as of late, and promised 100k tests a day, but the implementation of this plan was sketchy. Now I'm inclined to think that this government could well double down on the testing question.

I see no indication that Novacyt is involved other than having provided a few testing kits during the development phase.

That might be worrying, but not when it comes to Novacyt shares.

I agree Rich. For what it's worth, pharma company Moderna stated it aimed to release its vaccine this autumn at the earliest, and this would be reserved for medical workers at first.
So I wouldn't sell before the summer either.

Anders_uk : all I ever asked for was an apology. But even that seems too much for some.

So just a few days ago, a number of people were believing and forecefully stating that today Novacyt would release a huge RNS.

When I and other told them it wasn't reasonable, we were called names.

Will the rampers apologise now ?

I'd order for 2 or 3 months worth of production at full capacity. Because sourcing raw materials has become hard, hence bigger are probably valued by the suppliers.

In addition, the raw materials might be partly used in the fabrication process of other tests in the companie's line-up ; so even if orders dry up for the Wuflu test, it's not like 100% of the raw materials orders would be wasted.

I'm not completely sure that the figures quoted in the RNS are solely related to the sales of tests, but regardless, I suspect that Primerdesign has seen an increase in the sales of its instruments. That'd be because health organisations around the world regularly complain about the lack of machines to analyse the tests.

In addition, this pandemic has demonstrated the need for mobile testing teams - cf. drive-through tests.
Although I haven't yet encountered such reports, it is also possible that teams of medics have been fielded to visit potentially infected persons in order to test them. A portable PCR instrument such as the genesig q16 would be perfect to process the results on the spot, and decided whether the patients must be brought to a hospital.

Yeah, exactly.

It's pretty pathetic to read all these fairytale believers hoping for their dreams to materialise, and then accuse people more grounded in reality of being """derampers""".

It was positive but not a source of particular joy. It just went back to normal. There is no reason to expect the next RNS to be so substantial that it'll make the stock gain 1€ .

Too soon to have meaty announcements from the RNS. Wait a few more weeks.

Uh no, there are no indications in your quotes that a tie-up with GSK and AZN is in the cards.